Calamos Advisors LLC Buys 62,218 Shares of Penumbra, Inc. $PEN

Calamos Advisors LLC boosted its stake in shares of Penumbra, Inc. (NYSE:PEN) by 1,334.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,882 shares of the company’s stock after acquiring an additional 62,218 shares during the period. Calamos Advisors LLC’s holdings in Penumbra were worth $21,962,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC boosted its holdings in shares of Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock valued at $26,000 after purchasing an additional 82 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Penumbra by 2,700.0% in the fourth quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Motiv8 Investments LLC bought a new stake in shares of Penumbra in the fourth quarter worth about $27,000. Morse Asset Management Inc purchased a new stake in shares of Penumbra in the fourth quarter worth about $39,000. Finally, Farther Finance Advisors LLC boosted its stake in Penumbra by 27.1% during the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after buying an additional 38 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Zacks Research cut Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $374.00 target price on shares of Penumbra in a research report on Thursday, June 11th. Evercore reiterated an “outperform” rating and set a $320.00 target price on shares of Penumbra in a research report on Monday, July 6th. Wall Street Zen raised shares of Penumbra to a “hold” rating in a report on Saturday, May 9th. Finally, Citigroup reduced their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $360.33.

Penumbra Stock Performance

Penumbra stock opened at $316.32 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. The firm has a market capitalization of $12.44 billion, a P/E ratio of 72.89, a price-to-earnings-growth ratio of 1.97 and a beta of 0.70. Penumbra, Inc. has a 1-year low of $221.26 and a 1-year high of $362.41. The company’s 50-day moving average is $320.27 and its 200 day moving average is $329.78.

Penumbra (NYSE:PEN) last announced its earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.24). The business had revenue of $374.76 million for the quarter, compared to analysts’ expectations of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.83 EPS. Research analysts forecast that Penumbra, Inc. will post 5.04 EPS for the current year.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.